Microplastics and Misinformation: What Science Really Says
November 12, 2025
Brand Name :
Piportil
Synonyms :
pipotiazine
Class :
Antipsychotics
Dosage Forms & StrengthsÂ
Solution Â
25 mg Â
50 mg Â
Take a dose of 5 to 20 mg orally daily
Administer an initial dose of 25 mg intramuscularly as test dose followed by 25 to 50 mg after 4 to 7 days
Administer a maintenance dose of 50 to 100 mg intramuscularly in every 4 weeks
Maximum dose should not be more than 200 mg in every 4 weeks
Not determined Â
Refer to adult dosingÂ
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
aluminum hydroxide/magnesium carbonateÂ
may diminish the absorption of Antacids
may decrease the therapeutic effect of each other when combined
may decrease the therapeutic effect of cabergoline
metoclopramide increases the toxicity of antipsychotic agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
pipotiazine: it may decrease the stimulatory activities of benzphetamine
it may increase the neurotoxic effect of antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
it may increase the risk of adverse effect of amphetamines
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may enhance the hypotensive effects
may enhance the adverse effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may increase the hypotensive effect of beta blockers
may increase the hypotensive effect of beta blockers
may increase the toxic effect of amphetamines
may increase the hypotensive effect of blood pressure-lowering agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the toxic effect of seizure threshold-lowering potential agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may have an increased hypotensive effect when combined with antipsychotic agents
they decrease the absorption of antipsychotic agents
they decrease the absorption of antipsychotic agents
antipsychotic agents increase the effect of beta-blockers
Could potentially amplify the toxicity of antipsychotic agents
The efficacy of guanethidine could be reduced by the presence of antipsychotic agents
Could potentially amplify the toxicity of antipsychotic agents
cimetidine: they may decrease the therapeutic effect of antipsychotics
topiramate: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
abiraterone: it may decrease the metabolism of pipotiazine
acebutolol: it may increase the serum concentration of pipotiazine
acetazolamide: it may increase the risk of CNS depression with pipotiazine
benperidol: it may increase the risk of CNS depression with pipotiazine
benzocaine: it may increase the risk of CNS depression with pipotiazine
benzyl alcohol: it may increase the risk of CNS depression with pipotiazine
Actions and SpectrumÂ
pipotiazine works by blocking dopamine receptors in the brain. It reduces the excessive dopamine activity that is believed to contribute to the positive symptoms of schizophrenia.
Frequency not defined Â
DrowsinessÂ
Nasal stuffinessÂ
Dry mouthÂ
InsomniaÂ
AgitationÂ
Weight gain Â
Jaundice Â
Hypotension Â
ECG changes Â
Venous thromboembolismÂ
Cardiac arrhythmiasÂ
Pulmonary embolism Â
Mild leukopeniaÂ
Tardive dyskinesia Â
AkathisiaÂ
Contact skin sensitization Â
Photosensitivity Â
Ocular changeÂ
Tremor Â
RigidityÂ
AkinesiaÂ
Neuroleptic malignant syndrome Â
Glucose intoleranceÂ
Black Box WarningÂ
NoneÂ
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
pipotiazine affects serotonin receptors. It is less potent at these receptors compared to dopamine D2 receptors, the interaction with serotonin receptors can contribute to its therapeutic effects and may also influence its side effect profile.Â
PharmacodynamicsÂ
pipotiazine consists alpha-adrenergic blocking properties. This action can contribute to its sedative effects, which can be beneficial in treating agitation and aggressive behavior in individuals with psychotic disorders. Â
PharmacokineticsÂ
Absorption  Â
pipotiazine is absorbed from the gastrointestinal tract after oral administration.Â
DistributionÂ
pipotiazine is distributed throughout the body.Â
MetabolismÂ
pipotiazine is metabolized in the liver through metabolic pathways.Â
Elimination and excretionÂ
pipotiazine is excreted through the kidneys.Â
AdministrationÂ
pipotiazine is administered orally and intramuscularly and available in the form of solution.Â
Patient information leafletÂ
Generic Name: pipotiazineÂ
Why do we use pipotiazine?Â
pipotiazine is indicated for the treatment of schizophrenia.Â
pipotiazine also used in the maintenance treatment of chronic non-agitated schizophrenic patients.